Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.…
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
Zevra Therapeutics (NASDAQ: ZVRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 61 employees.
The shares were at 8.760 USD on 20 November 2026, down 0.6% over 52 weeks. Its 52-week range is 8.010 USD to 14.96 USD: the price is 41.4% below the high and 9.4% above the low.
At a market capitalisation of 521.26M USD, it trades at 7.2 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 78% for ZVRA.
Zevra Therapeutics reports return on equity of 53.8%, an operating margin of 31.5% and revenue up 44.9% year over year.
It holds more cash than debt, a net cash position of 194.34M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 23.00 USD is 162.6% above the current price. The next earnings report is expected on 8 March 2027.